<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04126538</url>
  </required_header>
  <id_info>
    <org_study_id>GNI-F647-1703</org_study_id>
    <nct_id>NCT04126538</nct_id>
  </id_info>
  <brief_title>Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics</brief_title>
  <official_title>Pirfenidone Capsule in Patients With Chronic Kidney Disease G2 and G3a Study on Safety and Pharmacokinetics of Single Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Continent Pharmaceutical Co, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Continent Pharmaceutical Co, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and pharmacokinetic characteristics of pirfenidone capsules in chronic&#xD;
      kidney disease G2 and G3a patients, and to provide a basis for the phase II clinical trial&#xD;
      program&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentrations of pirfenidone</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of pirfenidone</measure>
    <time_frame>up to 24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>up to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Renal Insufficiency</condition>
  <arm_group>
    <arm_group_label>Patient group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with chronic kidney disease take pirfenidone capsule 400mg once orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy subjects take pirfenidone capsule 400mg once orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirfenidone capsule</intervention_name>
    <description>In the patient group, pirfenidone capsule was taken orally once for 400mg</description>
    <arm_group_label>Patient group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pirfenidone capsule</intervention_name>
    <description>Healthy subjects took pirfenidone capsule 400mg once orally</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. patients with chronic kidney disease, both male and female（Patient group）;&#xD;
&#xD;
          2. 18-70 years old, including 18 years old and 70 years old（Patient group）;&#xD;
&#xD;
          3. weight: male ≥50kg, female ≥45kg, 18≤BMI≤26 (BMI= weight (kg)/height 2 (m2))（Patient&#xD;
             group）;&#xD;
&#xD;
          4. the stage of chronic kidney disease was G2 or G3a, indicating mild or moderate&#xD;
             decrease in GFR, i.e., glomerular filtration rate was 45≤eGFR(ml/min/1.73m2) ≤89&#xD;
             (calculated according to ckd-epi formula)（Patient group）;&#xD;
&#xD;
          5. from 24h before the start of the study to the end of the study, subjects who agree to&#xD;
             abstain from tobacco, alcohol, fruit juice, caffeine and tea（Patient group）;&#xD;
&#xD;
          6. I have had a detailed understanding of the nature, significance, possible benefits,&#xD;
             possible inconvenience and potential risks of the trial before the study, and I have&#xD;
             volunteered to participate in the clinical trial. I am able to communicate well with&#xD;
             the investigator, comply with the requirements of the whole study, and have the&#xD;
             ability to understand and sign the written informed consent.（Patient group）;&#xD;
&#xD;
          7. gender: Chinese healthy subjects, male and female（Control group）;&#xD;
&#xD;
          8. 18-70 years old, including 18 years old and 70 years old（Control group）;&#xD;
&#xD;
          9. weight: male ≥50kg, female ≥45kg, 18≤BMI≤26 (BMI= weight (kg)/height 2 (m2))（Control&#xD;
             group）;&#xD;
&#xD;
         10. from 24h before the start of the study to the end of the study, subjects who agree to&#xD;
             abstain from tobacco, alcohol, fruit juice, caffeine and tea（Control group）;&#xD;
&#xD;
         11. those who have detailed understanding of the nature, significance, potential benefits,&#xD;
             possible inconveniences and potential risks of the trial before the study, who have&#xD;
             volunteered to participate in the clinical trial, who can communicate well with the&#xD;
             investigator, comply with the requirements of the whole study, and who are able to&#xD;
             understand and sign a written informed consent（Control group）;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. （Physician visits） have participated in any other clinical trials within the first&#xD;
             three months of the trial（Patient group）;&#xD;
&#xD;
          2. (preliminary) of any process may affect test security, or drug in the body of the&#xD;
             disease, not including chronic kidney disease (CKD), including but not limited to:&#xD;
             heart, liver, gastrointestinal tract, immune system and respiratory system always or&#xD;
             the existing system diseases (especially for any impact on drug absorption of&#xD;
             gastrointestinal diseases (such as irritable bowel syndrome symptoms, bowel disease or&#xD;
             inflammatory bowel disease), active pathological bleeding (such as peptic ulcer),&#xD;
             urticaria, eczema, dermatitis, epilepsy, allergic rhinitis, asthma, etc.)（Patient&#xD;
             group）;&#xD;
&#xD;
          3. (consultation) allergy: if there are two or more drugs, food allergy history&#xD;
             (including experimental drugs), lactose intolerance（Patient group）;&#xD;
&#xD;
          4. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common&#xD;
             liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin,&#xD;
             aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme&#xD;
             inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol,&#xD;
             isoniazid, sulfonamide)（Patient group）;&#xD;
&#xD;
          5. (consultation) failure to follow a uniform diet (such as intolerance to standard&#xD;
             meals, etc.) or difficulty swallowing（Patient group）;&#xD;
&#xD;
          6. (consultation) unable to tolerate venipuncture and/or having a history of blood or&#xD;
             acupuncture（Patient group）;&#xD;
&#xD;
          7. (consultation) patients who have been drinking excessive amounts of tea, coffee or&#xD;
             caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking&#xD;
             any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.)&#xD;
             within 24 hours before the first administration of the drug（Patient group）;&#xD;
&#xD;
          8. (consultation) previous binge drinking (i.e., male drinking more than 28 units per&#xD;
             week and female drinking more than 21 units per week (1 unit contains 14g alcohol,&#xD;
             such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had&#xD;
             regularly consumed alcohol (more than 14 units per week) during the 6 months prior to&#xD;
             the trial; Or who had taken any alcoholic product within 24 hours of initial&#xD;
             administration（Patient group）;&#xD;
&#xD;
          9. (consultation) those who had donated blood or suffered massive bleeding (greater than&#xD;
             450 mL) within 3 months before the first administration of the study, or who planned&#xD;
             to donate blood or blood components during the study period or within 3 months after&#xD;
             the end of the study（Patient group）;&#xD;
&#xD;
         10. (consultation) acute disease during the screening phase before study or before study&#xD;
             medication（Patient group）;&#xD;
&#xD;
         11. (consultation) patients who had taken food or drinks containing enzymes that can&#xD;
             induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice,&#xD;
             orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before&#xD;
             the first administration were studied（Patient group）;&#xD;
&#xD;
         12. pregnant or lactating women, and subjects (or their partners) who have a pregnancy&#xD;
             plan during the trial and within 3 months after the end of the study and who do not&#xD;
             agree to use non-drug contraception during the trial（Patient group）;&#xD;
&#xD;
         13. (consultation) those who have had surgery within three months before the screening&#xD;
             period, or who are planning to have surgery during the study period, and those who&#xD;
             have had surgery that will affect drug absorption, distribution, metabolism and&#xD;
             excretion（Patient group）;&#xD;
&#xD;
         14. (consultation) previous history of drug abuse or drug abuse（Patient group）;&#xD;
&#xD;
         15. (consultation) persons who have smoked more than 5 cigarettes per day in the 14 days&#xD;
             before screening, or who cannot stop using any tobacco products during the&#xD;
             trial（Patient group）;&#xD;
&#xD;
         16. screening for smoking or using any tobacco products up to admission（Patient group）;&#xD;
&#xD;
         17. screening phase physical examination, vital signs measurement, electrocardiogram&#xD;
             examination, laboratory examination (hematuria routine, blood coagulation function,&#xD;
             blood pregnancy (women of childbearing age only)) and investigator determination of&#xD;
             clinically significant abnormalities (excluding abnormalities caused by chronic kidney&#xD;
             disease). Abnormal liver function examination (ALT, AST, ALP, gamma GT, TP, Alb, A/G,&#xD;
             t-bil, d-bil) suggested liver disease or liver injury. Renal function test SCr &gt; 400&#xD;
             mol/L; Abnormal blood electrolyte examination (K+, Na+, Cl-, Ca2+) suggested high&#xD;
             potassium or acidosis.（Patient group）&#xD;
&#xD;
         18. nicotine positive test（Patient group）;&#xD;
&#xD;
         19. alcohol breath test with test results greater than 0.0mg/100ml（Patient group）;&#xD;
&#xD;
         20. positive urine drug screening（Patient group）;&#xD;
&#xD;
         21. hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis&#xD;
             spirochete antibody positive, or HIV antibody positive（Patient group）;&#xD;
&#xD;
         22. the investigator considers that there are any circumstances that may affect the&#xD;
             subject's informed consent or adherence to the study protocol, or participation in the&#xD;
             study may affect the study results or their own safety.（Patient group）;&#xD;
&#xD;
         23. （Physician visits）those who participated in any other clinical trials three months&#xD;
             prior to the trial（Control group）;&#xD;
&#xD;
         24. (preliminary) of any process may affect test security, or drug in the body of the&#xD;
             disease, including but not limited to: heart, liver, kidney, endocrine, the digestive&#xD;
             tract, immune system and respiratory system always or the existing system diseases&#xD;
             (especially cardiovascular diseases including cardiovascular disease risk, any impact&#xD;
             on drug absorption of gastrointestinal diseases (such as irritable bowel syndrome&#xD;
             symptoms, bowel disease or inflammatory bowel disease), active pathological bleeding&#xD;
             (such as peptic ulcer), urticaria, eczema, dermatitis, epilepsy, allergic rhinitis,&#xD;
             asthma, etc.)（Control group）;&#xD;
&#xD;
         25. (consultation) allergy: if there are two or more drugs, food allergy history&#xD;
             (including experimental drugs), lactose intolerance（Control group）;&#xD;
&#xD;
         26. (consultation) any drugs that inhibit or induce drug metabolism in the liver (common&#xD;
             liver enzyme inducers: barbiturates, carbamazepine, aminoximate, griseofulvin,&#xD;
             aminopropyl, phenytoin, gromitol, rifampin, dexamethasone; Common liver enzyme&#xD;
             inhibitors: chlorpromazine, cimetidine, ciprofloxacin, metronidazole, chloramphenicol,&#xD;
             isoniazid, sulfonamide); Or have used any medicines (including Chinese herbal&#xD;
             medicines) or health supplements within 14 days prior to initial&#xD;
             administration（Control group）;&#xD;
&#xD;
         27. (consultation) failure to follow a uniform diet (such as intolerance to standard&#xD;
             meals, etc.) or difficulty swallowing（Control group）;&#xD;
&#xD;
         28. (consultation) unable to tolerate venipuncture and/or having a history of blood or&#xD;
             acupuncture（Control group）;&#xD;
&#xD;
         29. (consultation) patients who have been drinking excessive amounts of tea, coffee or&#xD;
             caffeinated drinks (more than 8 cups a day, 1 cup =250mL) for a long time; Or taking&#xD;
             any food or beverage containing caffeine (such as coffee, strong tea, chocolate, etc.)&#xD;
             within 24 hours before the first administration of the drug（Control group）;&#xD;
&#xD;
         30. (consultation) previous binge drinking (i.e., male drinking more than 28 units per&#xD;
             week and female drinking more than 21 units per week (1 unit contains 14g alcohol,&#xD;
             such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine); Or who had&#xD;
             regularly consumed alcohol (more than 14 units per week) during the 6 months prior to&#xD;
             the trial; Or who had taken any alcoholic product within 24 hours of initial&#xD;
             administration（Control group）;&#xD;
&#xD;
         31. (consultation) those who had donated blood or suffered massive bleeding (greater than&#xD;
             450 mL) within 3 months before the first administration of the study, or who planned&#xD;
             to donate blood or blood components during the study period or within 3 months after&#xD;
             the end of the study（Control group）;&#xD;
&#xD;
         32. (consultation) acute disease during the screening phase before study or before study&#xD;
             medication（Control group）;&#xD;
&#xD;
         33. (consultation) patients who had taken food or drinks containing enzymes that can&#xD;
             induce or inhibit liver metabolism (e.g., grapefruit, mango, pitaya, grape juice,&#xD;
             orange juice, etc., rich in flavonoids or citrus glycosides) within 24 hours before&#xD;
             the first administration were studied（Control group）;&#xD;
&#xD;
         34. pregnant or lactating women, and subjects (or their partners) who have a pregnancy&#xD;
             plan during the trial and within 3 months after the end of the study and who do not&#xD;
             agree to use non-drug contraception during the trial（Control group）;&#xD;
&#xD;
         35. (consultation) those who have had surgery within three months before the screening&#xD;
             period, or who are planning to have surgery during the study period, and those who&#xD;
             have had surgery that will affect drug absorption, distribution, metabolism and&#xD;
             excretion（Control group）;&#xD;
&#xD;
         36. (consultation) previous history of drug abuse or drug abuse（Control group）;&#xD;
&#xD;
         37. (consultation) persons who have smoked more than 5 cigarettes per day in the 14 days&#xD;
             before screening, or who cannot stop using any tobacco products during the&#xD;
             trial（Control group）;&#xD;
&#xD;
         38. screening for smoking or using any tobacco products up to admission（Control group）;&#xD;
&#xD;
         39. screening phase physical examination, vital signs measurement, electrocardiogram&#xD;
             examination, b-mode ultrasound examination, laboratory examination [blood routine,&#xD;
             urine routine, blood biochemistry, blood coagulation function, blood pregnancy (women&#xD;
             of childbearing age only)], and the investigator judged that abnormalities were&#xD;
             clinically significant（Control group）;&#xD;
&#xD;
         40. those with positive nicotine test results（Control group）;&#xD;
&#xD;
         41. alcohol breath test with test results greater than 0.0mg/100ml（Control group）;&#xD;
&#xD;
         42. positive urine drug screening（Control group）;&#xD;
&#xD;
         43. hepatitis b surface antigen positive, or hepatitis c antibody positive, or syphilis&#xD;
             spirochete antibody positive, or HIV antibody positive（Control group）;&#xD;
&#xD;
         44. the investigator considers that there are any circumstances that may affect the&#xD;
             subject's informed consent or adherence to the study protocol, or participation in the&#xD;
             study may affect the study results or their own safety.（Control group）.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaojun Shaojun, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wuhan Union Hospital, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shaojun Shi, Doctor</last_name>
    <phone>027-85726085</phone>
    <email>sjshicn@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Wuhan Union Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaojun Shi, Doctor</last_name>
      <phone>027-85726085</phone>
      <email>sjshicn@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>October 10, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>October 9, 2021</last_update_submitted>
  <last_update_submitted_qc>October 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Renal Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pirfenidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

